Patients, physicians, and others with a stake in nonalcoholic steatohepatitis (NASH) – a chronic condition caused by the buildup of fat and inflammation in the liver – convened for a roundtable to discuss a new survey sponsored by Intercept Pharmaceuticals, Inc. The NASH TRUTH (Time to Get Real About Liver Health) Survey examined the impact of communication barriers, knowledge gaps, and social stigma on patients with NASH and the healthcare providers who treat them.
In a series of video interviews, roundtable participants discuss the disease, how it has affected them, and what the future holds for those living with and treating NASH. You’ll also find more information on the survey, the disease, and ongoing clinical trials through the links below.